Press Releases

May 15, 2024 8:30 AM
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

PaxMedica today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq.

Read More
May 7, 2024 8:30 AM
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy.

PaxMedica provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders.

Read More
April 23, 2024 8:31 AM
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

PaxMedica expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi.

Read More
April 16, 2024 4:30 PM
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

PaxMedica today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.

Read More
April 11, 2024 4:31 PM
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

PaxMedica today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.

Read More
March 13, 2024 9:30 AM
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

PaxMedica is pleased to share our vision and progress with the wider community

Read More
December 6, 2023 7:50 AM
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

PaxMedica unveiled a Fireside Chat video featuring Howard Weisman, Chairman and CEO, providing a detailed company update with insights into recent achievements and advancements.

Read More
November 22, 2023 6:00 PM
PaxMedica Announces Closing of $7.0 Million Public Offering

Closing previously announced public offering.

Read More
November 20, 2023 9:15 AM
PaxMedica Announces Pricing of $7.0 Million Public Offering

Proceeds to Be Used to Advance Company's Development Programs

Read More
November 7, 2023 8:03 AM
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.

Read More
November 2, 2023 8:35 AM
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

Marks Important Step Prior to Filing NDA for African Sleeping Sickness

Read More
October 31, 2023 8:03 AM
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

The newly acquired data from RLS will play a crucial role in bolstering PaxMedica's ongoing efforts to support the submission for the approval of PAX-101

Read More
October 30, 2023 11:42 AM
PaxMedica Announces 1-for-17 Reverse Stock Split

As a result of the reverse stock split, each 17 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock.

Read More
October 26, 2023 2:00 PM
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder

Read More
October 26, 2023 8:00 AM
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

• Key Guidance Regarding NDA Filing Obtained

Read More
October 18, 2023 10:10 AM
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

Read More
October 10, 2023 8:05 AM
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023

PaxMedica announced its Gold Sponsorship of The BRAIN Foundation's esteemed Synchrony Symposia 2023.

Read More
August 30, 2023 8:00 AM
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Howard Weisman, Chief Executive Officer, will present a corporate overview on Tuesday, September 12, 2023 at 3:00pm EDT at the Lotte New York Palace Hotel. In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference.

Read More
August 16, 2023 8:30 AM
PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Announces Additional Management Changes; Independent Directors Now Majority of Board

Read More
August 9, 2023 4:15 PM
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update

PaxMedica provided a business update and reported financial results for the second quarter 2023, ended June 30, 2023.

Read More
July 24, 2023 8:00 AM
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results - These results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness

Read More
July 6, 2023 8:00 AM
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC

VoxNova is the first purpose-built limited distribution specialty pharmacy benefit manager that is focused on ASD. The Company’s mission is to provide compassionate care and critical oversight using groundbreaking therapies for the treatment of people living with ASD. Under the agreement, VoxNova will have exclusive access to PaxMedica’s PAX-101 intravenous suramin in the United States for a period of up to seven years.

Read More
June 22, 2023 8:00 AM
PaxMedica Comments on Common Stock Volatility

The management and Board of Directors of PaxMedica are aware of the recent market volatility in the company’s common stock. PaxMedica is not aware of any news that might be relevant to the recent share price fluctuations, however management takes its fiduciary responsibility very seriously, and have engaged the services of Shareholder Intelligence Services LLC (“ShareIntel”) to better understand the investor base and the trading behavior around the company’s securities.

Read More
June 20, 2023 8:30 AM
PaxMedica CEO Interviewed by The BRAIN Foundation

CEO, Howard Weisman, participated in a webcast on Saturday, June 17th, hosted by The BRAIN Foundation. The core content of the webcast was an interview with Mr. Weisman by The BRAIN Foundation’s co-founder, Sarika Agrawal.

Read More
June 14, 2023 8:00 AM
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder

PaxMedica has submitted a request to the South African Health Products Regulatory Authority (SAHPRA), seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101. This trial will seek to enroll a total of 30 subjects with confirmed ASD, ages 4 to 18, at multiple sites in South Africa. This is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the Company announced the results of its prior Phase II trial in 2021. Enrollment is expected to begin in Q4 2023, following SAHPRA’s potential approval later this summer.

Read More
June 8, 2023 8:00 AM
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder

PaxMedica has entered into an agreement with PoloMar Health to investigate the use of emodin in a clinical program as a potential treatment for patients with autism spectrum disorder.

Read More
June 1, 2023 8:00 AM
PaxMedica Completes HAT-301 Registrational Trial for PAX-101

The eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers.

Read More
May 15, 2023 4:30 PM
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

PaxMedica provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.

Read More
April 19, 2023 8:30 AM
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month

PaxMedica announced that Chief Executive Officer Howard Weisman will ring the Nasdaq Stock Market closing bell on Wednesday April 19, 2023. This comes to celebrate PaxMedica’s listing of its common shares on the Nasdaq Capital Market in August 2022 and April’s Autism Awareness Month.

Read More
March 29, 2023 7:20 PM
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results

PaxMedica provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

Read More
March 20, 2023 8:00 AM
PaxMedica Holds Meeting of Scientific Advisory Board

PaxMedica announced that it held a Scientific Advisory Board meeting on March 10-12, 2023. A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States.

Read More
February 15, 2023 7:30 AM
PaxMedica Releases 2022 Shareholder Letter

PaxMedica released a 2022 shareholder letter discussing its recent accomplishments and upcoming milestones.

Read More
February 3, 2023 8:00 AM
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

PaxMedica, Inc. has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together “Lind”).

Read More
January 20, 2023 1:30 PM
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event

PaxMedica today announced that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26 th .

Read More
December 14, 2022 8:00 AM
PaxMedica, Inc. Launches Updated Corporate Website at

PaxMedica announced that the Company has launched a newly updated corporate website at .

Read More
November 22, 2022 8:00 AM
PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

PaxMedica announced it will be presenting at the Benchmark Company’s 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022 at the New York Athletic Club in New York City.

Read More
November 17, 2022 8:20 PM
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

PaxMedica announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").

Read More
November 15, 2022 8:00 AM
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

PaxMedica provided a business update and reported financial results for the third quarter of 2022, ended September 30, 2022.

Read More
November 8, 2022 8:00 AM
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

PaxMedica announced that it has initiated a Phase 3 trial, HAT-301, as part of its strategic plan to obtain US market approval of PAX-101 (intravenous suramin).

Read More
October 24, 2022 8:00 AM
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

PaxMedica announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer. In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica’s pipeline products. The initial program underway is targeting antipurinergic drug therapies.

Read More